11/21/2024

Janusmed kön och genus

Janusmed kön och genus – Vaccin mot covid-19 (mRNA)

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Vaccin mot covid-19 (mRNA)

Vaccin mot covid-19 (mRNA)

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. Kelada M, Anto A, Dave K, Saleh SN. The Role of Sex in the Risk of Mortality From COVID-19 Amongst Adult Patients: A Systematic Review. Cureus. 2020;12(8):e10114.

  2. Lakbar I, Luque-Paz D, Mege JL, Einav S, Leone M. COVID-19 gender susceptibility and outcomes: A systematic review. PLoS One. 2020;15(11).

  3. Mesas AE, Cavero-Redondo I, Álvarez-Bueno C, Sarriá Cabrera MA, Maffei de Andrade S, Sequí-Dominguez I et al. Predictors of in-hospital COVID-19 mortality: A comprehensive systematic review and meta-analysis exploring differences by age, sex and health conditions. PLoS One. 2020;15(11):e0241742.

  4. Figliozzi S, Masci PG, Ahmadi N, Tondi L, Koutli E, Aimo A et al. Predictors of adverse prognosis in COVID-19: A systematic review and meta-analysis. Eur J Clin Invest. 2020;50(10):e13362.

  5. Ortolan A, Lorenzin M, Felicetti M, Doria A, Ramonda R. Does gender influence clinical expression and disease outcomes in COVID-19? A systematic review and meta-analysis. Int J Infect Dis. 2020;99:496-504.

  6. Centrum för epidemiologi och samhällsmedicin. Kön och risk för allvarlig sjukdom och död i covid-19. Stockholm: Centrum för epidemiologi och samhällsmedicin (CES); 2021.

  7. Falagas ME, Mourtzoukou EG, Vardakas KZ. Sex differences in the incidence and severity of respiratory tract infections. Respir Med. 2007;101(9):1845-63.

  8. Wray S, Arrowsmith S. The Physiological Mechanisms of the Sex-Based Difference in Outcomes of COVID19 Infection. Front Physiol. 2021;12:627260.

  9. Griffith DM, Sharma G, Holliday CS, Enyia OK, Valliere M, Semlow AR et al. Men and COVID-19: A Biopsychosocial Approach to Understanding Sex Differences in Mortality and Recommendations for Practice and Policy Interventions. Prev Chronic Dis. 2020;17:E63.

  10. Schiffer VMMM, Janssen EBNJ, van Bussel BCT, Jorissen LLM, Tas J, Sels JEM et al. The "sex gap" in COVID-19 trials: a scoping review. EClinicalMedicine. 2020;29:100652.

  11. European Medicines Agency (EMA). Note for guidance on preclinical pharmacological and toxicological testing of vaccines (CPMP/SWP/465/95) [updated 1997-12-17, cited 2021-04-08].

  12. Klein SL, Marriott I, Fish EN. Sex-based differences in immune function and responses to vaccination. Trans R Soc Trop Med Hyg. 2015;109(1):9-15.

  13. Flanagan KL, Klein SL, Skakkebaek NE, Marriott I, Marchant A, Selin L et al. Sex differences in the vaccine-specific and non-targeted effects of vaccines. Vaccine. 2011;29(13):2349-54.

  14. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-2615.

  15. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R et al; COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403-416.

  16. Demonbreun AR, Sancilio A, Velez ME, Ryan DT, Pesce L, Saber R et al. COVID-19 mRNA Vaccination Generates Greater Immunoglobulin G Levels in Women Compared to Men. J Infect Dis. 2021;224(5):793-797.

  17. Wheeler SE, Shurin GV, Yost M, Anderson A, Pinto L, Wells A et al. Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects. Microbiol Spectr. 2021;9(1):e0034121.

  18. Watson S, Caster O, Rochon PA, den Ruijter H. Reported adverse drug reactions in women and men: Aggregated evidence from globally collected individual case reports during half a century. EClinicalMedicine. 2019;17:100188.

  19. Kroenke K, Spitzer RL. Gender differences in the reporting of physical and somatoform symptoms. Psychosom Med. 1998;60(2):150-5.

  20. Barsky AJ, Peekna HM, Borus JF. Somatic symptom reporting in women and men. J Gen Intern Med. 2001;16(4):266-75.

  21. Holm L, Ekman E, Jorsäter Blomgren K. Influence of age, sex and seriousness on reporting of adverse drug reactions in Sweden. Pharmacoepidemiol Drug Saf. 2017;26(3):335-343.

  22. Assessment report - Comirnaty (tozinameran). European Medicines Agency (EMA) [www]. [updated 2021-02-19, cited 2021-04-08].

  23. Assessment report - COVID-19 Vaccine Moderna (modified mRNA, encoding full length SARS-CoV-2 spike protein (CX-024414)). European Medicines Agency (EMA) [www]. [updated 2021-03-11, cited 2021-04-08].

  24. EudraVigilance. Amsterdam: European Medicines Agency (EMA) [updated 2021-04-17, cited 2021-04-23.]

  25. COVID-19 vaccine safety update - SPIKEVAX. European Medicines Agency (EMA) [www]. [updated 2021-07-14, cited 2021-10-06].

  26. COVID-19 vaccine safety update - COMIRNATY. European Medicines Agency (EMA) [www]. [updated 2021-07-14, cited 2021-10-06].

  27. Karlstad Ø, Hovi P, Husby A, Härkänen T, Selmer RM, Pihlström N et al. SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents. JAMA Cardiol. 2022.

  28. Statistikdatabas för diagnoser. Stockholm: Socialstyrelsen. 2020 [cited 2021-10-06.]

  29. Cooper LT, Keren A, Sliwa K, Matsumori A, Mensah GA. The global burden of myocarditis: part 1: a systematic literature review for the Global Burden of Diseases, Injuries, and Risk Factors 2010 study. Glob Heart. 2014;9(1):121-9.

  30. Mattsson G, Levin C, Magnusson P. ABC om - perikardit och myokardit. Lakartidningen. 2018;115.

  31. Statistik för vaccination mot covid-19. Folkhälsomyndigheten [www]. [updated 2021-04-09, cited 2021-04-23].

  1. Kelada M, Anto A, Dave K, Saleh SN. The Role of Sex in the Risk of Mortality From COVID-19 Amongst Adult Patients: A Systematic Review. Cureus. 2020;12(8):e10114.
  2. Lakbar I, Luque-Paz D, Mege JL, Einav S, Leone M. COVID-19 gender susceptibility and outcomes: A systematic review. PLoS One. 2020;15(11).
  3. Mesas AE, Cavero-Redondo I, Álvarez-Bueno C, Sarriá Cabrera MA, Maffei de Andrade S, Sequí-Dominguez I et al. Predictors of in-hospital COVID-19 mortality: A comprehensive systematic review and meta-analysis exploring differences by age, sex and health conditions. PLoS One. 2020;15(11):e0241742.
  4. Figliozzi S, Masci PG, Ahmadi N, Tondi L, Koutli E, Aimo A et al. Predictors of adverse prognosis in COVID-19: A systematic review and meta-analysis. Eur J Clin Invest. 2020;50(10):e13362.
  5. Ortolan A, Lorenzin M, Felicetti M, Doria A, Ramonda R. Does gender influence clinical expression and disease outcomes in COVID-19? A systematic review and meta-analysis. Int J Infect Dis. 2020;99:496-504.
  6. Centrum för epidemiologi och samhällsmedicin. Kön och risk för allvarlig sjukdom och död i covid-19. Stockholm: Centrum för epidemiologi och samhällsmedicin (CES); 2021.
  7. Falagas ME, Mourtzoukou EG, Vardakas KZ. Sex differences in the incidence and severity of respiratory tract infections. Respir Med. 2007;101(9):1845-63.
  8. Wray S, Arrowsmith S. The Physiological Mechanisms of the Sex-Based Difference in Outcomes of COVID19 Infection. Front Physiol. 2021;12:627260.
  9. Griffith DM, Sharma G, Holliday CS, Enyia OK, Valliere M, Semlow AR et al. Men and COVID-19: A Biopsychosocial Approach to Understanding Sex Differences in Mortality and Recommendations for Practice and Policy Interventions. Prev Chronic Dis. 2020;17:E63.
  10. Schiffer VMMM, Janssen EBNJ, van Bussel BCT, Jorissen LLM, Tas J, Sels JEM et al. The "sex gap" in COVID-19 trials: a scoping review. EClinicalMedicine. 2020;29:100652.
  11. European Medicines Agency (EMA). Note for guidance on preclinical pharmacological and toxicological testing of vaccines (CPMP/SWP/465/95) [updated 1997-12-17, cited 2021-04-08].
  12. Klein SL, Marriott I, Fish EN. Sex-based differences in immune function and responses to vaccination. Trans R Soc Trop Med Hyg. 2015;109(1):9-15.
  13. Flanagan KL, Klein SL, Skakkebaek NE, Marriott I, Marchant A, Selin L et al. Sex differences in the vaccine-specific and non-targeted effects of vaccines. Vaccine. 2011;29(13):2349-54.
  14. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-2615.
  15. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R et al; COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403-416.
  16. Demonbreun AR, Sancilio A, Velez ME, Ryan DT, Pesce L, Saber R et al. COVID-19 mRNA Vaccination Generates Greater Immunoglobulin G Levels in Women Compared to Men. J Infect Dis. 2021;224(5):793-797.
  17. Wheeler SE, Shurin GV, Yost M, Anderson A, Pinto L, Wells A et al. Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects. Microbiol Spectr. 2021;9(1):e0034121.
  18. Watson S, Caster O, Rochon PA, den Ruijter H. Reported adverse drug reactions in women and men: Aggregated evidence from globally collected individual case reports during half a century. EClinicalMedicine. 2019;17:100188.
  19. Kroenke K, Spitzer RL. Gender differences in the reporting of physical and somatoform symptoms. Psychosom Med. 1998;60(2):150-5.
  20. Barsky AJ, Peekna HM, Borus JF. Somatic symptom reporting in women and men. J Gen Intern Med. 2001;16(4):266-75.
  21. Holm L, Ekman E, Jorsäter Blomgren K. Influence of age, sex and seriousness on reporting of adverse drug reactions in Sweden. Pharmacoepidemiol Drug Saf. 2017;26(3):335-343.
  22. Assessment report - Comirnaty (tozinameran). European Medicines Agency (EMA) [www]. [updated 2021-02-19, cited 2021-04-08].
  23. Assessment report - COVID-19 Vaccine Moderna (modified mRNA, encoding full length SARS-CoV-2 spike protein (CX-024414)). European Medicines Agency (EMA) [www]. [updated 2021-03-11, cited 2021-04-08].
  24. EudraVigilance. Amsterdam: European Medicines Agency (EMA) [updated 2021-04-17, cited 2021-04-23.]
  25. COVID-19 vaccine safety update - SPIKEVAX. European Medicines Agency (EMA) [www]. [updated 2021-07-14, cited 2021-10-06].
  26. COVID-19 vaccine safety update - COMIRNATY. European Medicines Agency (EMA) [www]. [updated 2021-07-14, cited 2021-10-06].
  27. Karlstad Ø, Hovi P, Husby A, Härkänen T, Selmer RM, Pihlström N et al. SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents. JAMA Cardiol. 2022.
  28. Statistikdatabas för diagnoser. Stockholm: Socialstyrelsen. 2020 [cited 2021-10-06.]
  29. Cooper LT, Keren A, Sliwa K, Matsumori A, Mensah GA. The global burden of myocarditis: part 1: a systematic literature review for the Global Burden of Diseases, Injuries, and Risk Factors 2010 study. Glob Heart. 2014;9(1):121-9.
  30. Mattsson G, Levin C, Magnusson P. ABC om - perikardit och myokardit. Lakartidningen. 2018;115.
  31. Statistik för vaccination mot covid-19. Folkhälsomyndigheten [www]. [updated 2021-04-09, cited 2021-04-23].